Leishmaniasis is a life-threatening zoonosis of which dogs are the major reservoir and sandflies are the vectors. Until now, the prevalence of canine leishmaniasis (CanL) in the Slovenian dog population was unknown. Epidemiological data, eye swabs and blood samples were taken from 465 dogs born in Slovenia and older than one year. Commercial ELISA kits and real-time PCR were used. For ELISA-positive samples, an immunofluorescence antibody test (IFAT) was performed. Descriptive statistics were used to characterise the samples. The one-sample nonparametric chi-square test was used to test whether the categories of a variable were equally distributed. A 59.9% proportion of the recruited dogs had travelled to endemic regions and 62.1% of them had not been protected by insect repellents. Skin symptoms that might be CanL-related were described in 109 of the dogs’ histories (23.4%), inappetence and/or weight loss in 25 (5.4%), and anaemia, intermittent fever, and/or lymphadenopathy in 19 (4.1%). At the time of recruitment, all dogs were asymptomatic. All samples were PCR negative, nine (1.9%) were ELISA positive, but none were IFAT positive. Five of the nine ELISA-positive dogs were non-travellers. We conclude that the seroprevalence of canine leishmaniasis of 1.9 % in the autochthonous Slovenian dog population may pose a risk of endemic spread of the disease.

Leishmaniasis is a zoonotic disease which has worldwide importance and is hard to control and treat. Researchers have not yet developed a protective vaccine for humans in the light of current studies. Various experimental animal models are being used since; i) Leishmania has different species and vectors, ii) there are still many clinical, pathological and immunological issues that have to be investigated, iii) new non-toxic medical recipes to have maximum yield in a short time have to be investigated, iv) protective vaccination have to be developed. Mouse, hamster, dog, rodent, and non-human primates are among these animal models. None of them has the same clinical features, pathogenesis and immunology with the disease in human. However, rodents, dogs, and monkeys, which are the last host of the parasite, are among the most preferred models in recent days. Considering the different clinical forms of the disease, it is best to decide which Leishmania species to work with which animal. This review is intended to guide the researchers in choosing an appropriate animal model for leishmaniasis studies.

Blood glycated hemoglobin concentration reflects long-term serum glucose levels in dogs. In this study, the effects of several diseases on blood glycated hemoglobin levels have been evaluated. For this study, blood samples were drawn from 93 unhealthy dogs. The animals were distributed into 10 groups according to pathological process (group 1, digestive problems; group 2, leishmaniasis; group 3, anemia; group 4, dermatological disorders; group 5, urinary problems; group 6, cardiorespiratory problems; group 7, diabetes mellitus; group 8, insulinoma; group 9, general diseases; group 10, control group). Blood glucose and glycated hemoglobin concentrations and hemoglobin and hematocrit values were analyzed in all the animals. In diabetic dogs, a strong increase in blood glycated hemoglobin was observed when compared with the other groups (P < 0.01). In contrast, dogs with insulinoma showed a decrease in blood glycated hemoglobin, though significant differences were not reported in all cases. No change in blood glycated hemoglobin concentrations were reported in dogs affected by other diseases. So, we can suppose that only the chronic alterations in glucose metabolism (chronic hyper- or hypoglycemia) can induce significant changes on the blood glycated hemoglobin concentrations in dogs.

Leishmania donovani, dogs (exper.), liposome-encapsulated meglumine antimoniate (LEMA) vs. unencapsulated meglumine antimoniate, LEMA was 700 times more efficacious than the encapsulated drug, liposomes can markedly reduce the drug dosage required for equivalent treatment of visceral leishmaniasis

Leishmaniasis is a vector-borne zoonotic disease that is common in the world. Because of the difficulties in the treatment and control of the disease, the disease has gained popularity among researchers. Today, however, no vaccine has been developed for human protection. Considering the fact that the vector can survive in a wide ecosystem and the disease can be detected in many mammals such as humans, dogs, rodents, prevention from leishmaniasis and treatment of the disease require a combined intervention. The toxic effects of the drugs used in the treatment of leishmaniasis, the expensive treatment and the resistance of the parasite to the drug have led to the research of alternative treatment methods. This review is intended to provide an overview of leishmaniasis alternative treatment practices and to guide new researchs.

Leishmania donovani, amastigotes from dog marrow macrophages, ultrastructure